{"id":59140,"date":"2021-07-01T11:38:43","date_gmt":"2021-07-01T09:38:43","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=59140"},"modified":"2021-07-01T12:57:30","modified_gmt":"2021-07-01T10:57:30","slug":"ema-non-approva-il-vaccino-astrazeneca-prodotti-in-india","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/ema-non-approva-il-vaccino-astrazeneca-prodotti-in-india\/","title":{"rendered":"EMA does not approve the AstraZeneca vaccine manufactured in India"},"content":{"rendered":"

Ema says no to the use of AstraZeneca's Indian anti-Covid vaccine<\/h1>\n

"Covishield", produced with a similar technology but at a lower cost than the original AstraZeneca anti-Covid serum, "does not currently comply with EU standards".<\/p>\n

Sputnik News \u2013 June 30, 2021<\/a><\/p>\n

\"\"The European Medicines Agency has rejected the use of the anti-Covid serum "Covishield" produced by the Anglo-Swedish pharmaceutical company AstraZeneca in factories in India. The preparation is similar to Vaxzevria, authorized by the EMA for use in Europe.<\/p>\n

\u201cEven if it uses a production technology similar to Vaxzevria (AstraZeneca's vaccine), Covishield does not currently comply with EU standards, \u2013 reads a note from the EMA, reported by Ansa. \u2013 This is because vaccines are biological products. Even small differences in production conditions can lead to differences in the final product, and EU law requires production sites and the manufacturing process to be assessed and approved as part of the permitting process."<\/p>\n

The decision by the European regulator has raised concern in the African Union, since the Covishield is widely used.<\/p>\n

We remind you that in the EU the EMA has approved 4 anti-Covid vaccines for the implementation of the vaccination campaign against the coronavirus:<\/p>\n

\n
\n
\n
    \n
  1. Pfizer-BioNTech (2 doses, manufactured by American and German company);<\/li>\n
  2. Moderna (2 doses, produced by a US company);<\/li>\n
  3. Johnson & Johnson (single-serve, manufactured by US company)<\/li>\n
  4. AstraZeneca (2 doses, Anglo-Swedish company).<\/li>\n<\/ol>\n<\/div>\n
    <\/div>\n
    At the moment the Ema is evaluating<\/a> the authorization of other anti-Covid serums, including the Chinese Sinovac, the German CureVac and the American Novavax and the Russian vaccine developed by the Gamaleya Center "Sputnik V".<\/div>\n<\/div>\n<\/div>\n

    Just today Russian President Vladimir Putin he has declared<\/a> to have been vaccinated against Covid-19 with the preparation of the Gamaleya Center.<\/p>\n

    Related news:\u00a0AstraZeneca COVID-19 vaccine authorized for emergency use by the World Health Organization<\/a><\/p>\n

    The story of the Serum Institute, the largest vaccine manufacturer in the world. A pharmaceutical giant born from a snake bite<\/a><\/p>\n

    Covishield: India puts pressure on EU for vaccine pass approval<\/a><\/p>\n

    Russia. 20,000 infections in one day: Putin sets an example and gets vaccinated<\/a><\/p>\n

     <\/p>\n

    \"\"<\/p>","protected":false},"excerpt":{"rendered":"

    Ema dice no all’uso del vaccino anti-Covid indiano di AstraZeneca “Covishield”, prodotto con una tecnologia simile ma a minor costo rispetto al siero anti-Covid originale di AstraZeneca, “attualmente non risponde alle norme dell’Ue”. Sputnik News – 30 giugno 2021 L’Agenzia europea per i medicinali ha bocciato l’uso del siero anti-Covid “Covishield” prodotto dalla societ\u00e0 farmaceutica …<\/p>","protected":false},"author":4,"featured_media":59146,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59140","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/59140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=59140"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/59140\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/59146"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=59140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=59140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=59140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}